Successful go-public transaction and over $475 million raised this year provides cash runway through multiple clinical ...

EST Oruka Therapeutics (ORKA) files to sell 8.72M shares of common stock for holders Published first on TheFly – the ultimate ...

Wedbush analyst David Nierengarten maintained a Buy rating on Oruka Therapeutics (ORKA – Research Report) today and set a price target of ...

Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) is one of 39 publicly-traded companies in the “Diagnostic substances” industry, but how does it contrast to its competitors? We will compare Oruka ...

Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) is one of 39 public companies in the “Diagnostic substances” industry, but how does it weigh in compared to its peers? We will compare Oruka ...

Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque ...

Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka's mission is to offer patients suffering from chronic skin ...

View upcoming earnings forecasts and in-depth analysis of company forecasts.

Board members include Lawrence Klein, Ph.D., CEO of Oruka Therapeutics; Erin Lavelle, former Chief Operating Officer and Chief Financial Officer at ProfoundBio and Eliem Therapeutics; Chris Cain ...